BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19036092)

  • 21. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
    Ducas RA; Seftel MD; Ducas J; Seifer C
    J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 23. Arsenic-based therapy benefits leukemia patients.
    FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
    [No Abstract]   [Full Text] [Related]  

  • 24. Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission.
    Au WY; Ma SK; Ooi C; Liang R; Kwong YL
    J Clin Oncol; 2000 Oct; 18(19):3435-7. PubMed ID: 11013284
    [No Abstract]   [Full Text] [Related]  

  • 25. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
    Yamamoto Y; Sasaki M; Oshimi K; Sugimoto K
    Acta Haematol; 2009; 122(1):52-3. PubMed ID: 19816009
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
    Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
    Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
    [No Abstract]   [Full Text] [Related]  

  • 27. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
    Yan J; Chen X; Shao J
    Eur J Haematol; 2013 Nov; 91(5):470-1. PubMed ID: 23869721
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
    Sui M; Zhang Z; Zhou J
    Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
    Spencer A; Firkin F
    Aust N Z J Med; 1999 Jun; 29(3):385-6. PubMed ID: 10868510
    [No Abstract]   [Full Text] [Related]  

  • 30. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
    Sanz MA; Fenaux P; Lo Coco F;
    Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
    Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
    Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide.
    Au WY; Chan GC; Chim CS; Shek TW; Ooi GC; Ho WK; Kwong YL
    J Clin Oncol; 2001 Oct; 19(19):3993-5. PubMed ID: 11579122
    [No Abstract]   [Full Text] [Related]  

  • 33. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D; Nasr R; de The H
    Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
    Haanen C; Vermes I
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
    Carney DA
    Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of acute promyelocytic leukemia with arsenic trioxide.
    Tamm I; Paternostro G; Zapata JM
    N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
    [No Abstract]   [Full Text] [Related]  

  • 38. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

  • 39. [Research advances on effect of arsenic trioxide on tumor].
    Feng CQ; Ma WL; Zheng WL
    Ai Zheng; 2002 Dec; 21(12):1386-9. PubMed ID: 12520754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide.
    Au WY; Fung AT; Ma ES; Chan CH; Wong KF; Chim CS; Liang RH; Kwong YL
    Br J Haematol; 2005 Dec; 131(5):632-5. PubMed ID: 16351640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.